Topic: An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics. Clinical Relevance: The availability of biologic agents for the treatment of human eye disease has altered practice patterns for the management of noninfectious uveitis. Current guidelines are insufficient to assure optimal use of noncorticosteroid systemic immunomodulatory agents. Methods: An international expert steering committee comprising 9 uveitis specialists (including both ophthalmologists and rheumatologists) identified clinical questions and, together with 6 bibliographic fellows trained in uveitis, conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol systematic review of the literature (English language studies from January 1996 through June 2016; Medline [OVID], the Central Cochrane library, EMBASE, CINAHL, SCOPUS, BIOSIS, and Web of Science). Publications included randomized controlled trials, prospective and retrospective studies with sufficient follow-up, case series with 15 cases or more, peer-reviewed articles, and hand-searched conference abstracts from key conferences. The proposed statements were circulated among 130 international uveitis experts for review. A total of 44 globally representative group members met in late 2016 to refine these guidelines using a modified Delphi technique and assigned Oxford levels of evidence. Results: In total, 10 questions were addressed resulting in 21 evidence-based guidance statements covering the following topics: when to start noncorticosteroid immunomodulatory therapy, including both biologic and nonbiologic agents; what data to collect before treatment; when to modify or withdraw treatment; how to select agents based on individual efficacy and safety profiles; and evidence in specific uveitic conditions. Shared decision-making, communication among providers and safety monitoring also were addressed as part of the recommendations. Pharmacoeconomic considerations were not addressed. Conclusions: Consensus guidelines were developed based on published literature, expert opinion, and practical experience to bridge the gap between clinical needs and medical evidence to support the treatment of patients with noninfectious uveitis with noncorticosteroid immunomodulatory agents.
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative / Dick, A. D.; Rosenbaum, J. T.; Al-Dhibi, H. A.; Belfort, R.; Brezin, A. P.; Chee, S. P.; Davis, J. L.; Ramanan, A. V.; Sonoda, K. -H.; Carreno, E.; Nascimento, H.; Salah, S.; Salek, S.; Siak, J.; Steeples, L.; Accorinti, M.; Acharya, N.; Adan, A.; Agrawal, R.; Akkoc, N.; Al Ghamdi, S.; Al Ghamdi, T.; Al Saati, A.; Alsabaani, N.; Al-Shamarani, M.; Bachta, A.; Barisani-Asenbauer, T.; Beare, N.; Porto, F. B. O.; Blanco, R.; Yee, A. C. S.; Chandran, V.; Chiquet, C.; Chng, H. H.; Cimbalas, A.; Cimino, L.; Cordero-Coma, M.; Cristobal, C.; Cuevas, M.; Eurico da Fonseca, J.; de Boer, J.; de la Torre, A.; De Schryver, I.; Derzko-Dzulynsky, L.; Diaz-Valle, D.; Merino, C. E. D.; Facsko, A.; Figueira, L.; Fonollosa, A.; Fortin, E.; Gale, R.; Galeazzi, M.; Garcia, S.; Garcia Ruiz de Morales, J. M.; Gaspersic, N.; Goldstein, D.; Guedes, M.; Guex-Crosier, Y.; Gul, A.; Hamam, R.; Haroon, M.; Hasegawa, K.; Heiligenhaus, A.; Hooper, C.; Hwang, Y. -S.; Hwang, D. -K.; Juanola, X.; Kaburaki, T.; Kadayifcilar, S.; Kempen, J.; Kezuka, T.; Kherani, A.; Kirsimae, M.; Kotaniemi, K.; Kraut, A.; Kubicka-Trzaska, A.; Kuffova, L.; Lightman, S.; Lim, L.; Lim, W. K.; Mccluskey, P.; Mcguire, M.; Mirabelli, P.; Miserocchi, E.; Misiuk-Hojlo, M.; Muccioli, C.; Munoz, S.; Murphy, C.; Murray, P.; Nagy, Z.; Namba, K.; Neri, P.; Nguyen, Q.; O'Gradaigh, D.; Omair, M.; Otsa, K.; Ozyazgan, Y.; Pablo, F.; Paroli, M. P.; Pleyer, U.; Poor, G.; Proenca, R.; Rabinovitch, T.; Read, R.; Rebrov, M.; Recillas-Gispert, C.; Rothova, A.; Schwartzman, S.; Seve, P.; Sharma, S.; Sims, J.; Sohar, N.; Suhler, E.; Szanto, S.; Szepessy, Z.; Tappeiner, C.; Thorne, J.; Tugal Tutkun, I.; Turno-Krecicka, A.; Van Calster, J.; van der Horst-Bruinsma, I.; Vidovic Valentincic, N.; Vitale, A.; Voorduin Ramos, S.; Vukojevic, N.; Wakefield, D.; Willermain, F.; Yalcindag, N.; Yamamoto, J. H.; Yeh, S.; Zemaitiene, R.; Ziouzina, O.. - In: OPHTHALMOLOGY. - ISSN 0161-6420. - 125:5(2018), pp. 757-773. [10.1016/j.ophtha.2017.11.017]
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative
Cimino L.;Murphy C.;Neri P.;
2018
Abstract
Topic: An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics. Clinical Relevance: The availability of biologic agents for the treatment of human eye disease has altered practice patterns for the management of noninfectious uveitis. Current guidelines are insufficient to assure optimal use of noncorticosteroid systemic immunomodulatory agents. Methods: An international expert steering committee comprising 9 uveitis specialists (including both ophthalmologists and rheumatologists) identified clinical questions and, together with 6 bibliographic fellows trained in uveitis, conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol systematic review of the literature (English language studies from January 1996 through June 2016; Medline [OVID], the Central Cochrane library, EMBASE, CINAHL, SCOPUS, BIOSIS, and Web of Science). Publications included randomized controlled trials, prospective and retrospective studies with sufficient follow-up, case series with 15 cases or more, peer-reviewed articles, and hand-searched conference abstracts from key conferences. The proposed statements were circulated among 130 international uveitis experts for review. A total of 44 globally representative group members met in late 2016 to refine these guidelines using a modified Delphi technique and assigned Oxford levels of evidence. Results: In total, 10 questions were addressed resulting in 21 evidence-based guidance statements covering the following topics: when to start noncorticosteroid immunomodulatory therapy, including both biologic and nonbiologic agents; what data to collect before treatment; when to modify or withdraw treatment; how to select agents based on individual efficacy and safety profiles; and evidence in specific uveitic conditions. Shared decision-making, communication among providers and safety monitoring also were addressed as part of the recommendations. Pharmacoeconomic considerations were not addressed. Conclusions: Consensus guidelines were developed based on published literature, expert opinion, and practical experience to bridge the gap between clinical needs and medical evidence to support the treatment of patients with noninfectious uveitis with noncorticosteroid immunomodulatory agents.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0161642017324466-main.pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
606.73 kB
Formato
Adobe PDF
|
606.73 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
